NVIDIA Invests in CHARM Therapeutics, a Nobel Laureate-Founded AI Biotech Advancing Next-Gen Menin Inhibitor for AML

On September 2, AI Biomedical CompanyCHARM TherapeuticsAnnounced the completion of an oversubscribed Series B financing, raising a total of$80 million(Approximately RMB 570 million)

This round byThe World's Largest Venture Capital Firm, New Enterprise Associates(NEA) andSR One, a venture capital arm of GlaxoSmithKlineCo-led by existing investors OrbiMed, F-Prime, Khosla Ventures andNVIDIAParticipate.

The funds raised will be used forAdvancing the Next Generation of Treatments for Acute Myeloid Leukemia (AML)Development of Menin inhibitors.

CHARM Therapeutics was founded inJune 2022, headquartered in London, UK.

The company isNobel Prize in Chemistry laureate and protein field expert, Professor David Baker, as well as scientists

Co-founded by Laksh Aithani.

The core technology platform of CHARM Therapeutics isProtein-Ligand Co-folding PlatformDragonFold, based on deep learning algorithms, can completeProtein-Ligand Co-foldingModeling.

Currently, CHARM Therapeutics is utilizingDragonFold , Develop a New GenerationMENIN inhibitorTreatment of Acute Myeloid Leukemia.

Acute Myeloid Leukemia (AML) is a rapidly progressing aggressive cancer of the blood and bone marrow, characterized by the uncontrolled growth of abnormal myeloid cells that fail to mature properly.

Despite advances in targeted therapy, the prognosis for many patients with AML remains poor, leading to significant toxicity in many patients and greatly limiting clinical outcomes.

CHARM Therapeutics Inc. stated that the candidate drug developed by the company not only effectively addresses drug resistance but also achieves significant tumor regression in preclinical models.

In addition, the company expects the molecule to be effective at low doses in humans without prolonging the QTc interval, andDoes not inhibit the enzyme responsible for drug interactions.

The clinical development of this drug is expected to begin in early 2026.

Recommended Reading